Skip to main content
TipRanks
Go Ultimate75% OFF

Cerus (CERS) Q3 2026 Earnings Report

776 Followers

CERS Q3 2026 EPS Results

Actual EPS
$0.00
Consensus EPS
-$0.01
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.00

CERS Q3 2026 Revenue Results

Actual Revenue
$57.71M
Expected Revenue
$63.25M
Beat/Miss
Missed by -$5.54M
YoY Revenue Growth
+9.52%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/02/2026
Time
After Close
Conference Call
Monday, November 2, 2026
CERS Upcoming Earnings

Cerus's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

CERS Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 02, 2026|% Change Since:-21.19%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Cerus reported double-digit product revenue growth, reaffirmed full-year guidance, continued ISC and platelet adoption, stronger cash generation, positive adjusted EBITDA for the tenth consecutive quarter, and positive Phase III REDeS top-line results. The principal challenges were geopolitical and foreign-exchange headwinds in EMEA, a year-over-year gross-margin decline, declining government contract revenue, pending regulatory questions, and CE Mark timing now expected in late 2027. The number and significance of the stated achievements outweighed the stated challenges.

Company Guidance

Management reaffirmed full year 2026 product revenue guidance of $229 million to $231 million, including full year 2026 IFC sales of $23 million to $25 million, and expects essentially all ISC sales will be in kit form in 2027. Cerus’ operating priorities include delivering sustainable double digit annual growth; it expects INT200 placements in EMEA to continue in the fourth quarter and some relief in Q4 from foreign exchange headwinds, expects CE Mark clearance in late 27 followed by a limited market release targeting centers of excellence in Europe, and considers the first half of 27 a reasonable expectation for the full REDeS data analysis, while providing no 2027 product revenue guidance.

  • Product Revenue Growth and Guidance ReaffirmedThird-quarter 2026 product revenue was $57.7 million, up 10% year-over-year. Product revenue for the first nine months increased 14% to $168.8 million. Cerus reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, including ISC sales guidance of $23 million to $25 million.
  • Nearly 800,000 Doses of Blood Components SupportedThird-quarter kit sales represented nearly 800 thousand doses of transfusable blood components, supporting Cerus' mission to expand access to safer blood.
  • North American Growth and Platelet Share GainsNorth American third-quarter product revenue increased 12% year-over-year and represented just over two-thirds of total product revenue. North American platelet kit and calculated platelet doses increased 5% year-over-year, outpacing underlying platelet market growth.
  • INTERCEPT Platelets Broadly Adopted in the United StatesINTERCEPT platelets are now used at all leading U.S. hospitals recognized in the latest U.S. News & World Report ranking.
  • Blood Centers of America Agreement Gaining TractionBlood Centers of America members account for more than half of all blood products distributed in the United States. Revenue growth from BCA member blood centers outpaced overall North American growth through the first three quarters, and new BCA centers adopted both ISC and platelet production and distribution.
  • Strong ISC Revenue and Volume GrowthISC product revenue increased to $5.6 million in the third quarter from $3.9 million in the prior-year quarter. On a dose-equivalent basis, ISC sales volume increased 7% sequentially. Management said ISC volumes grew approximately 80% in the third quarter and 60% year-to-date, according to the question's cited figures, and described ISC as a meaningful growth driver for years to come.
  • ISC Kit-Only Model Expanding Reach and MarginsCerus is transitioning ISC sales from finished therapeutics sold directly to hospitals to kits sold through blood centers. Ninety percent of ISC sales shipped during the quarter were in kit form, and the company expects essentially all ISC sales to be in kit form in 2027. Management stated that the kit model has a more attractive gross-margin profile and expands hospital and patient reach through blood-center distribution networks.
  • ISC Clinical and Commercial Adoption BenefitsManagement cited immediate access to fibrinogen and a five-day post-thaw shelf life as benefits of ISC. The longer shelf life can materially reduce waste, while free-thawed ISC can support more timely treatment in critical bleeding situations. At Grady Memorial Hospital, a unit of ISC has been kept thawed and ready for issue since the hospital adopted ISC in September 2025.
  • INT200 International Placements Exceeding ExpectationsInternational placements of the next-generation LED-based INT200 illuminator exceeded expectations and contributed strongly to third-quarter sales. Cerus expects the placement trend to continue in the fourth quarter and said the placements are establishing a foundation for further kit penetration.
  • Positive REDeS Phase III Top-Line ResultsThe Phase III REDeS study met its primary efficacy endpoint, demonstrating non-inferiority in adjusted hemoglobin increment for INTERCEPT-treated red blood cells compared with conventional red blood cells. There was no statistically significant difference between treatment and control arms for treatment-emergent adverse events, including the INTERCEPT RBC-specific antibody observed in the treatment arm; the antibodies were consistent with prior studies and resulted in no clinical impact.
  • Expanded Red Blood Cell Clinical Evidence BaseThe REDeS results add to clinical evidence from the STARS, SPARK, and ReCePI trials. Cerus described the completed REDeS trial as a significant milestone and said it has built the largest library of clinical evidence supporting pathogen reduction technology in red cell transfusion.
  • Red Cell Regulatory and Commercial PlanningCerus plans to complete the full REDeS clinical analysis, submit the clinical study report to regulators, and pursue publication and presentation. Subject to CE Mark approval, the company is planning a limited European market release targeting centers of excellence to generate real-world experience and inform its broader go-to-market strategy.
  • Progress on Gen 2 RBC SystemManagement said it made good progress on the Gen 2 red blood cell system during the third quarter and expects to discuss more specifics entering 2027. The Gen 2 system is expected to be the primary go-to-market system and would be submitted for approval after the Gen 1 device approval process.
  • Improving Profitability and Positive Adjusted EBITDACerus delivered its tenth consecutive quarter of positive adjusted EBITDA. Third-quarter adjusted EBITDA was $5.7 million compared with $5.0 million in the prior-year quarter. Management also said it has line of sight into achieving GAAP profitability.
  • Positive Operating Cash Flow and Stronger Balance SheetCash generation from operations was $3 million in the third quarter, driven in large part by close management of inventory levels during the first half of the year. Cash, cash equivalents, and short-term investments totaled $57.1 million as of September 30, 2026, up close to $1 million from June 30.
  • Sequential Gross-Margin ImprovementThird-quarter product gross margin was 52.4%, compared with 51.4% in the second quarter. Pricing and product mix, particularly the continued conversion to ISC kit sales, supported the sequential improvement.
  • Operating Expense LeverageThird-quarter operating expenses were $36.2 million, up 5% year-over-year, while product revenue grew 10%. Research and development expenses declined 10% year-over-year, reflecting completion of REDeS enrollment, lower INT200 development costs following the U.S. PMA submission, and completion of activities covered under the FDA contract.
  • Positive Progress in GermanyThe INITIATE post-market study of the INTERCEPT platelet system, conducted with the German Red Cross, continues to enroll at a healthy pace, with positive customer feedback. Cerus said Germany could represent a meaningful growth opportunity over the rest of the decade.
  • Continued Investment in Innovation and Market ExpansionManagement stated that the company is balancing financial progress with disciplined investment in technologies and capabilities supporting future growth, including product innovation, clinical evidence generation, market expansion, and red blood cell development.

CERS Earnings History

CERS earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)-0.00--0.01――
Nov 02, 20262026 (Q3)-0.010.000―
Jul 30, 20262026 (Q2)-0.01-0.01-0.0366.67% (+0.02)
Apr 30, 20262026 (Q1)-0.04-0.01-0.0475.00% (+0.03)
Mar 02, 20262025 (Q4)-0.01-0.01-0.010.00% (+0.00)
Nov 06, 20252025 (Q3)-0.030.00-0.02100.00% (+0.02)
Aug 05, 20252025 (Q2)-0.03-0.03-0.030.00% (+0.00)
May 01, 20252025 (Q1)-0.04-0.04-0.0520.00% (+0.01)
Feb 20, 20252024 (Q4)-0.01-0.01-0.010.00% (+0.00)
Oct 30, 20242024 (Q3)-0.03-0.02-0.0450.00% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed